- Switzerland
- /
- Biotech
- /
- SWX:KURN
Kuros Biosciences First Half 2024 Earnings: CHF0.01 loss per share (vs CHF0.14 loss in 1H 2023)
Kuros Biosciences (VTX:KURN) First Half 2024 Results
Key Financial Results
- Revenue: CHF31.8m (up 148% from 1H 2023).
- Net loss: CHF211.0k (loss narrowed by 96% from 1H 2023).
- CHF0.01 loss per share (improved from CHF0.14 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kuros Biosciences shares are up 2.5% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Kuros Biosciences (2 are concerning!) that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Kuros Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:KURN
Kuros Biosciences
A biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally.
Flawless balance sheet low.